Stock listing
OTC:SOMNF Somnomed Limited Stock
US listing (OTC) of Somnomed Limited · home listing ASX:SOM
Follow Somnomed Limited into a list and get an email when it puts out news.
Share price · OTC:SOMNF
$0.18 USD 0.00 (0.0%)
Close on Nov 10, 2026
- Day range
- $0.18 – $0.18 USDNov 10, 2026
- Market cap
- $70.22M USDAt the close on Nov 10, 2026 · price × 390.1M shares outstanding
- 52-week range
- $0.16 – $0.51 USDLowest and highest trades, Nov 11, 2025 – Nov 10, 2026
- Traded on an average day
- $18 USDMedian day 0 shares · 62 days with no trades · last 3 months, Aug 10, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:SOM · Home | $0.31 AUD | 0.00 (0.0%) | 88,000 | $0.31 | $0.31 | $0.31 | $0.31 | Close on Nov 20, 2026 |
| OTC:SOMNF | $0.18 USD | 0.00 (0.0%) | — | $0.18 | $0.18 | $0.18 | $0.18 | Close on Nov 10, 2026 |
| Frankfurt:RJV | €0.174 EUR | -0.001 (-0.6%) | — | €0.175 | €0.175 | €0.174 | €0.175 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 10, 2026 – Nov 6, 2026 · OTC:SOMNF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.18 | 0 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.18 | 0 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.18 | 0 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.18 | 0 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.18 | 0 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.18 | 0 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.18 | 0 | |
| $0.18 | 0.00 | 0.0% | $0.18 | $0.18 | $0.18 | 0 | |
| $0.18 | -0.06 | -25.0% | $0.16 | $0.18 | $0.16 | 4,000 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | 0.00 | 0.0% | $0.24 | $0.24 | $0.24 | 0 | |
| $0.24 | -0.21 | -46.7% | $0.24 | $0.24 | $0.24 | 1,700 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 | |
| $0.45 | 0.00 | 0.0% | $0.45 | $0.45 | $0.45 | 0 |
Splits
1 split · OTC:SOMNF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- OTC:SOMNF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Change in substantial holding
Latest deck · Aug 28, 2026
FY2026 Earnings Presentation
Earnings · 21 slides
Latest news
Annual General Meeting Proxy Form
Oct 16, 2026
Closed $0.24 (0.0%) on Oct 16, 2026
Notice of Annual General Meeting
Oct 16, 2026
Closed $0.24 (0.0%) on Oct 16, 2026
Chair Transition
Oct 16, 2026
Closed $0.24 (0.0%) on Oct 16, 2026
Notification of cessation of securities - SOM
Sep 4, 2026
Closed $0.45 (0.0%) on Sep 4, 2026
Change of Director's Interest Notice
Aug 28, 2026
Closed $0.45 (0.0%) on Aug 28, 2026
Full year results announcement FY26
Aug 27, 2026
Closed $0.45 (0.0%) on Aug 28, 2026
Full Year Statutory Accounts
Aug 27, 2026
Closed $0.45 (0.0%) on Aug 28, 2026
Securities Trading Policy
Aug 27, 2026
Closed $0.45 (0.0%) on Aug 28, 2026
Corporate Governance Statement
Aug 27, 2026
Closed $0.45 (0.0%) on Aug 28, 2026
Somnomed Limited on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 24 in the last 12 months · 178 in all · newest Nov 20, 2026 · oldest 2016
- Decks
- 55 decks · latest Aug 28, 2026
Where Somnomed Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:SOM · Home listing | ASX | Australia | AUD |
| LS Exchange:A0B7QA | LS Exchange | Germany | EUR |
| Lang & Schwarz:A0B7QA | Lang & Schwarz | Germany | EUR |
| gettex:RJV | gettex | Germany | EUR |
| OTC:SOMNF · This page | OTC | United States | USD |
| Dusseldorf:RJV | Dusseldorf | Germany | EUR |
| Frankfurt:RJV | Frankfurt | Germany | EUR |
| Munich:RJV | Munich | Germany | EUR |
| Stuttgart:RJV | Stuttgart | Germany | EUR |
| Tradegate:RJV | Tradegate | Germany | EUR |
Valuation
EV/sales 0.5× against a median of 2.9×: 3rd lowest of 10 Medical devices & supplies companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $56.40M AUD
- P/E
- Loss
- EV/sales
- 0.5×
- EV/EBITDA
- 8.7×
- Price/book
- 1.4×
- Gross margin
- 53.2%
- Operating margin
- 0.9%
- Net margin
- −2.3%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Somnomed Limited · ASX:SOM | US$45.09M | US$37.33M | n/a | 0.5× | 8.7× | 1.4× | −2.3% | 0.1× | n/a |
| Medimaging Integrated Solution Inc. · TWSE:6796 | US$48.03M | US$43.05M | 111× | 2.1× | 28.6× | 1.9× | 2.1% | 0.5× | n/a |
| Conexeu Sciences Inc. · NASDAQ:CNXU | US$47.79M | US$45.82M | n/a | n/a | n/a | 8.2× | n/a | 0.0× | 2.08 |
| Microbot Medical Inc. · NASDAQ:MBOT | US$45.67M | −US$16.16M | n/a | −38.6× | n/a | 0.7× | n/a | 0.0× | 1.82 |
| RenovoRx, Inc. · NASDAQ:RNXT | US$45.45M | US$35.27M | n/a | 12.7× | n/a | 4.9× | −469.0% | 0.0× | 1.71 |
| Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. · BIST:ONCSM | US$45.25M | US$45.28M | 31.7× | 2.9× | 7.5× | 4.5× | 9.0% | 0.1× | n/a |
| Bactiguard Holding AB · OMXSTO:BACTI_B | US$45.14M | US$54.81M | 76.6× | 2.6× | 12.5× | 1.5× | 2.8% | 0.5× | n/a |
| Nuo Therapeutics Inc · OTC:AURX | US$44.38M | US$44.30M | n/a | 7.3× | n/a | n/a | −31.5% | n/a | 0.73 |
| Ortoma AB Class B · OMXSTO:ORT_B | US$44.27M | US$38.13M | n/a | 11.7× | n/a | 2.6× | −197.7% | 0.0× | n/a |
| BrainCool AB · OMXSTO:BRAIN | US$43.31M | US$39.09M | n/a | 9.8× | n/a | 2.8× | −84.7% | 0.0× | n/a |
| Corentec Co., Ltd. · KRX:104540 | US$42.58M | US$24.07M | 8.5× | 0.3× | 2.3× | 0.7× | 6.4% | 0.0× | n/a |
| Median of the others | US$45.20M | US$41.07M | 54.1× | 2.9× | 10.0× | 2.6× | −14.7% | 0.0× | 1.77 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.84 AUD · Analysts' mean
- EPS, year to Jun 2027
- 0.020 · 2 analysts
- Revenue, year to Jun 2027
- 121.9M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Karen Borg | Chief Executive Officer and Executive Director |
| Terence Flitcroft | Company Secretary |
| Alison Bell | Sales Manager | UK |
Board
| Director | Role |
|---|---|
| Andrew Price | Non-Executive Director |
| Benjamin Gisz | Non-Executive Director |
| Karen Borg | Chief Executive Officer and Executive Director |
| Michael Gordon | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Apr 29, 2026 | −2.6% |
| Quarter to Sep 30, 2025 | Dec 3, 2025 | −1.2% |
| Q4 2025 | Aug 27, 2025 | +8.2% |
| Quarter to Mar 31, 2025 | May 30, 2025 | +4.8% |
| Q2 2025 | Feb 27, 2025 | 0.0% |
| Quarter to Sep 30, 2024 | Nov 27, 2024 | +46.3% |
| Q4 2024 | Aug 27, 2024 | −2.5% |
| Quarter to Mar 31, 2024 | Jun 27, 2024 · Before open | 0.0% |
| Q2 2024 | Feb 27, 2024 | +2.6% |
| Quarter to Sep 30, 2023 | Oct 30, 2023 · After close | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Aug 31, 2023 · After close | 0.0% |
| Q3 2023 | Apr 28, 2023 · Before open | 0.0% |
| Q2 2023 | Feb 22, 2023 | −13.1% |
| Q1 2023 | Oct 25, 2022 · Before open | +3.5% |
| Q4 2022 | Aug 23, 2022 · Before open | −0.8% |
| Q3 2022 | Apr 26, 2022 | 0.0% |
| Q2 2022 | Feb 21, 2022 · After close | −2.1% |
| Q1 2022 | Dec 1, 2021 | +1.4% |
| Q4 2021 | Aug 23, 2021 | 0.0% |
| Q3 2021 | Jun 2, 2021 | +6.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2026 Earnings Presentation | Earnings | 21 slides | Aug 28, 2026 |
| Investor Presentation (February 2026) | Investor deck | 20 slides | Feb 27, 2026 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 12 slides | Nov 27, 2025 |
| Canaccord Drug & Devices Conference 2025 | Conference | 9 slides | Oct 21, 2025 |
| FY2025 Earnings Presentation | Earnings | 21 slides | August 2025 |
| H1 FY25 Earnings Presentation | Earnings | 19 slides | February 2025 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 11 slides | Nov 27, 2024 |
| Investor Presentation (August 2024) | Investor deck | 19 slides | Aug 28, 2024 |
| Investor Presentation (April 2024) | Investor deck | 16 slides | Apr 9, 2024 |
| H1 2024 Earnings Presentation | Earnings | 24 slides | February 2024 |
Show 50 decks
This page holds 50 of 55 decks. Open Decks
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 114.5M | 111.5M | 91.7M | 83.6M | 72.6M | 62.7M | 57.3M | 58.9M | 52.4M | 49.3M |
| Cost of revenue | 53.6M | 44.8M | 36.5M | 37.8M | 33.4M | 28.8M | 27.3M | 24.3M | 20.5M | 20.5M |
| Gross profit | 60.9M | 66.7M | 55.1M | 45.8M | 39.2M | 33.9M | 30.0M | 34.6M | 31.9M | 28.8M |
| Research and development | 1.74M | 1.82M | 1.04M | 705.9K | 978.4K | 958.2K | 904.3K | 1.06M | 949.1K | 953.7K |
| Selling, general and administrative | 46.2M | 20.2M | 18.0M | 14.1M | 13.8M | 11.2M | 10.5M | 12.2M | 9.38M | 13.5M |
| Operating income | 976.0K | 3.62M | -8.33M | -4.07M | -4.13M | -651.4K | -941.0K | 918.5K | 2.00M | -3.73M |
| Depreciation and amortization | 5.49M | 5.75M | 5.78M | 5.12M | 3.94M | 3.84M | 3.09M | 2.30M | 1.68M | 1.23M |
| EBITDA | 6.46M | 9.36M | -2.55M | 1.04M | -195.3K | 3.19M | 2.14M | 3.22M | 3.68M | -2.50M |
| Interest expense | 464.0K | 398.5K | 3.17M | 2.63M | 380.3K | 469.2K | 473.1K | 205.3K | 199.6K | 20.4K |
| Income before tax | -458.0K | -763.9K | -11.3M | -7.05M | -3.50M | -733.9K | 747.0K | 607.2K | 1.84M | -3.76M |
| Income tax | 2.19M | 2.69M | 971.1K | 821.6K | 930.6K | 349.2K | 1.19M | 646.6K | 1.61M | 399.3K |
| Net income | -2.65M | -3.46M | -12.2M | -8.00M | -4.44M | -1.19M | -1.12M | -39.4K | 2.32M | -3.34M |
| Earnings per share, basic | -0.01 | -0.02 | -0.10 | -0.10 | -0.05 | -0.01 | -0.02 | -0.00 | 0.04 | -0.06 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.2M | 17.3M | 16.2M | 12.0M | 15.6M | 21.1M | 30.2M | 7.70M | 13.4M | 14.2M |
| Short-term investments | 0 | |||||||||
| Receivables | 11.6M | 11.2M | 7.93M | 9.03M | 9.20M | 8.22M | 6.13M | 7.12M | 10.4M | 6.62M |
| Inventory | 7.36M | 7.43M | 6.29M | 4.10M | 3.09M | 2.33M | 2.24M | 1.90M | 2.00M | 1.95M |
| Current assets | 38.9M | 43.1M | 35.1M | 27.5M | 30.3M | 34.1M | 40.2M | 20.2M | 29.0M | 26.4M |
| Property, plant and equipment | 13.9M | 11.1M | 12.7M | 9.12M | 10.3M | 10.2M | 3.25M | 5.69M | 4.49M | |
| Goodwill | 6.54M | 7.05M | 6.34M | 6.49M | 6.04M | 6.26M | 6.47M | 6.41M | 6.38M | 6.17M |
| Total assets | 75.0M | 81.0M | 69.8M | 62.5M | 58.1M | 56.2M | 61.7M | 34.8M | 45.7M | 41.2M |
| Accounts payable | 6.01M | 19.3M | 13.1M | 12.0M | 12.6M | 10.3M | 8.28M | 7.83M | 8.08M | 7.55M |
| Current liabilities | 23.3M | 28.6M | 19.9M | 18.4M | 23.8M | 16.2M | 18.8M | 16.0M | 11.5M | 9.95M |
| Long-term debt | 311.0K | 448.6K | 709.1K | 16.4M | 2.01M | 2.35M | 2.51M | 1.04M | ||
| Total debt | 5.46M | 8.03M | 6.72M | 23.5M | 12.0M | 8.91M | 15.5M | 3.60M | 1.44M | 122.5K |
| Total liabilities | 27.6M | 34.6M | 24.8M | 40.1M | 30.3M | 24.0M | 27.9M | 16.9M | 12.9M | 10.3M |
| Shareholders' equity | 47.4M | 46.4M | 45.0M | 22.4M | 27.8M | 32.2M | 33.8M | 17.8M | 36.1M | 32.2M |
| Shares outstanding | 216.3M | 211.9M | 120.7M | 82.1M | 82.1M | 82.0M | 66.0M | 70.8M | 55.6M | 53.7M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 8.28M | 7.78M | -6.33M | -3.88M | 1.86M | 2.71M | 5.19M | -6.55M | -9.47M | -2.68M |
| Capital spending | -3.26M | -2.42M | -1.39M | -6.41M | -8.79M | -4.13M | -2.19M | -1.34M | -2.01M | -2.39M |
| Free cash flow | 5.02M | 5.36M | -7.72M | -10.3M | -6.93M | -1.43M | 3.00M | -7.89M | -11.5M | -5.07M |
| Cash from investing | -5.74M | -3.98M | -5.34M | -6.41M | -8.47M | -4.37M | -1.83M | -1.63M | -2.20M | -2.74M |
| Cash from financing | -1.47M | -3.38M | 16.7M | 6.61M | 2.09M | -6.80M | 18.9M | 2.38M | 10.5M | 2.28M |
| Dividends paid | -20.1M | -4.96M | 0 | |||||||
| Share buybacks | -16.0K | 0 | -2.07M | 0 | 0 | 399.0K | -617.2K | -73.5K | -371.7K | -71.4K |
| Change in cash | -109.4K | 1.11M | 4.22M | -3.69M | -5.47M | -9.06M | 22.5M | -5.69M | -826.9K | -3.42M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Change in substantial holding | Nov 19, 2026 | Ownership change notice | ASX |
| Annual General Meeting Proxy Form | Oct 16, 2026 | Meeting notice | ASX |
| Notice of Annual General Meeting | Oct 16, 2026 | Meeting notice | ASX |
| Chair Transition | Oct 16, 2026 | Other filings | ASX |
| Change in substantial holding | Sep 28, 2026 | Ownership change notice | ASX |
| Notification of cessation of securities - SOM | Sep 4, 2026 | Financing | ASX |
| Change of Director's Interest Notice | Aug 28, 2026 | Ownership change notice | ASX |
| Change of Director's Interest Notice | Aug 28, 2026 | Ownership change notice | ASX |
| Change of Director's Interest Notice | Aug 28, 2026 | Ownership change notice | ASX |
| Change of Director's Interest Notice | Aug 28, 2026 | Ownership change notice | ASX |
All 178 filings
Cap table
Built by 6ix from Somnomed Limited’s releases
- Common shares
- 219,768,253
- Fully diluted
- 219,768,253
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 219,768,253 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 219,768,253 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alison Bell | Sales Manager | UK · Since at least Nov 4, 2026 |
| Andrew Price | Non-Executive Director · Since at least Nov 5, 2026 |
| Benjamin Gisz | Non-Executive Director · Since at least Nov 5, 2026 |
| Guy Russo | Non-Executive Chairman · Oct 16, 2026 – Oct 16, 2026 · Past |
| Karen Borg | Chief Executive Officer and Executive Director · Since at least Aug 18, 2026 |
| Michael Gordon | Non-Executive Director · Since at least Nov 5, 2026 |
| Terence Flitcroft | Company Secretary · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Somnomed Limited.